Success Metrics

Clinical Success Rate
95.7%

Based on 22 completed trials

Completion Rate
96%(22/23)
Active Trials
10(24%)
Results Posted
27%(6 trials)
Terminated
1(2%)

Phase Distribution

Ph early_phase_1
3
7%
Ph phase_2
10
24%
Ph phase_1
12
29%
Ph phase_4
4
10%
Ph not_applicable
10
24%
Ph phase_3
2
5%

Phase Distribution

15

Early Stage

10

Mid Stage

6

Late Stage

Phase Distribution41 total trials
Early Phase 1First-in-human
3(7.3%)
Phase 1Safety & dosage
12(29.3%)
Phase 2Efficacy & side effects
10(24.4%)
Phase 3Large-scale testing
2(4.9%)
Phase 4Post-market surveillance
4(9.8%)
N/ANon-phased studies
10(24.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.0%

22 of 25 finished

Non-Completion Rate

12.0%

3 ended early

Currently Active

10

trials recruiting

Total Trials

41

all time

Status Distribution
Active(10)
Completed(22)
Terminated(3)
Other(6)

Detailed Status

Completed22
Recruiting7
unknown6
Active, not recruiting3
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
41
Active
10
Success Rate
95.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (7.3%)
Phase 112 (29.3%)
Phase 210 (24.4%)
Phase 32 (4.9%)
Phase 44 (9.8%)
N/A10 (24.4%)

Trials by Status

recruiting717%
completed2254%
unknown615%
terminated12%
withdrawn25%
active_not_recruiting37%

Recent Activity

Clinical Trials (41)

Showing 20 of 41 trialsScroll for more
NCT00065676Phase 2

Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes

Completed
NCT07144293Phase 2

Improving Physical Ability and Cellular Senescence Elimination in HIV

Active Not Recruiting
NCT04785300Phase 1

ALSENLITE: Senolytics for Alzheimer's Disease

Active Not Recruiting
NCT07025226Early Phase 1

Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

Recruiting
NCT07628972Phase 1

Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD)

Recruiting
NCT05838560Phase 2

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Active Not Recruiting
NCT04907253Phase 2

Quercetin in Coronary Artery By-pass Surgery

Completed
NCT07433621Phase 1

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Recruiting
NCT06230861Not Applicable

Effects of Quercetin on Cardiometabolic Outcomes

Recruiting
NCT06940297Phase 2

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
NCT07380178Not Applicable

The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis

Completed
NCT05877235Not Applicable

Serum Concentration of Endogenous Estrogens and Sirtuin-1 After Administration of Atorvastatin and Quercetin:

Completed
NCT07182526Phase 2

Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome

Recruiting
NCT05422885Phase 1

Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

Completed
NCT06650891Phase 3

Quercetin Effect on Post-ceserean Pain

Completed
NCT06591767Not Applicable

Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia

Completed
NCT04313634Phase 2

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

Completed
NCT06355037Phase 2

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Recruiting
NCT01168739Not Applicable

Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body Stress Response

Completed
NCT05928546Phase 1

Effect of Quercetin in Treatment of Periodontitis

Unknown

Drug Details

Intervention Type
OTHER
Total Trials
41